ZetrOZ Systems Reports sam® Dramatically Improves the Treatment of Soft Tissue, Arthritis and Joint Issues Without Requiring Surgery or Pain Medication

July 15, 2020

ZetrOZ System reports sam® provides effective and safe treatment of soft tissue, arthritis and joint issues without the need for surgery or pain medication. The wearable device does so by stimulating blood flow for several hours per day to a localized region, delivering a powerful flow of nutrients to the site of an injury.

ZetrOZ Systems reports sam® administers 1.3 watts of low-intensity ultrasound energy at 3 megahertz frequency to accelerate biological healing processes and reduce pain. Harnessing the sustained delivery of low-intensity acoustic waves, the device stimulates the body’s natural repair process.

sam® is a safe and effective approach to healing tissue and easing pain. Instead of subjecting patients to time-consuming surgery with a lengthy recovery time and costly pain medication, the device gently massages users’ cells to promote collagen matrix production and cellular replication to heal damaged tissue.

sam® provides ultrasonic waves that penetrate five centimeters into tissue. This process improves circulation, oxygen and nutrient delivery. It also facilitates the removal of waste products, such as lactic acid, from the site of a musculoskeletal injury. In addition, sam® stimulates the tissue remodeling process. These processes give the device the unique ability to inhibit the inflammatory response and treat the injury itself – not just mask pain.

These are some of the reasons why sam® is the only continuous treatment, wearable mechanobiological device cleared by the FDA to treat deep tissue targets like knees, elbows, back and neck injuries.

Unlike traditional ultrasound treatments, sam® is FDA approved to provide treatment for four hours per day, versus 20 minutes per day. This expanded duration greatly improves the device’s ability to foster healing and pain relief. Additionally, traditional therapeutic ultrasound requires administration by a specialist onsite, thereby limiting the frequency of treatments. sam®, on the other hand, is easy and safe for patients to use at home on a daily basis – further increasing the treatment’s positive impact.

Transcutaneous Electrical Nerve Stimulation (TENS) controls pain by using electrical currents to stimulate nerves and block pain signals from being sent to the brain. While TENS and sam® have both proven successful in clinical studies for relieving pain, only sam® has the ability to accelerate the natural healing process through mechanical stimulation.

“We developed sam® to help people suffering from injuries and chronic pain break free from the traditional constraints of surgery and pain medication. While the treatment is highly effective, it is a natural, drug-free way to heal soft tissue and provide desperately needed pain relief – allowing users to reclaim their lives,” said George Lewis, chief executive officer of ZetrOZ Systems.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”